About us

life molecular imaging

Your Partner for
Molecular Imaging

With the development of novel PET tracers for molecular imaging, Life Molecular Imaging (LMI) is focusing on a key area of modern medicine. LMI strives to be a leader in the field of molecular imaging by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

Life Molecular Imaging

Our Mission

We Provide Innovative PET Tracers
to Reduce the Burden of the Diseases

Our mission is to develop novel PET Tracers in the area of Molecular Imaging that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

life molecular imaging

Our History

Life Molecular Imaging (LMI) was founded in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG by Piramal and is now part of the Life Healthcare Group.

LMI is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our flagship product Neuraceq® is used to detect the accumulation of amyloid proteins in the brain, which is considered a major cause of Alzheimer’s disease. Neuraceq® is nowadays approved and produced in many countries around the globe.

Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. It’s about making life better for everyone.

Key Milestones

Bayer spins out separate entity – Piramal Enterpises Ltd. becomes new owner

Neuraceq® approved by US & EU regulators

Acquired by Life Healthcare Group

life molecular imaging

Part of the Life Healthcare International Group

An integrated business including research and development laboratories.

Emilia Clarke
Life Healthcare

Market-leading globally diversified healthcare provider with a large hospital and clinic network in South Africa.


Visit website
Emilia Clarke
Life Molecular Imaging

LMI develops and commercialises radiopharmaceuticals used in molecular imaging and has a promising pipeline of products in development across the neurogenerative and cardiovascular areas.
life molecular imaging

Our Partners

We are serving our customers with the help of the most experienced partners in the area of ​​Molecular Imaging.

life molecular imaging

Compliance & Code of Conduct

Life Molecular Imaging is committed to the highest standards of ethical, moral and legal business conduct. Ethical business behaviour is the responsibility of every person in the company and is reflected not only in our relationships with each other but also with our customers, suppliers, clients, contractors, shareholders, and other stakeholders.

Being true to our customers, our environment, and our company, and respecting each other are the fundamental expectations of every Life Molecular Imaging employee and our business partners.

Our culture of compliance, which is fully supported by our senior management, is supported with clear and consistent policies, compliance training, and open communication channels. Life Molecular Imaging has developed its Compliance Program to meet the specific needs of the company and continually assesses the effectiveness of its Compliance Program. We respond quickly to concerns and identify risks, administering corrective action when appropriate.

The Life Healthcare Code of Conduct and related corporate policies are a key component of our commitment to high standards of business and personal ethics.

As member of EFPIA (European Federation of Pharmaceutical Industries Association) Life Molecular Imaging is committed to comply with the EFPIA codes of standard as well as with applicable national laws and regulations for an open and transparent relationship with stakeholders across healthcare including healthcare professionals (HCPs), EU institutions and patient organizations.

Please click for our transparency reporting (as Life Molecular Imaging) for Calendar Year: 2020, 2021, 2022 ,2023, 2024.

Please click for the Spanish transparency reporting (as Life Molecular Imaging) for Calendar Year: 2024

At Life Molecular Imaging we take violations against our Code of Conduct seriously: we thoroughly investigate known cases and take disciplinary actions where appropriate.

Ethics and Compliance Hotline:
Every Life Molecular Imaging representative (including company personnel and agents) has a duty to report any actual or suspected violations of any laws, regulations, government healthcare program requirements, internal policies and procedures, or inappropriate actions.

Employees, customers, business partners, and third parties may make report concerns by contacting the Life Healthcare Ethics Office at ethicsoffice@life.co.za  

All reports submitted to the Integrity Line are handled with discretion. LMI does not tolerate any form of retaliation against individuals who report any suspected improper, unethical or illegal conduct.

We at LMI also engage with our various suppliers around the world to ensure they comply with the general principles of LMI’s Supplier Code of Conduct.


Life Molecular Imaging Global Compliance Program

To obtain a copy of the Compliance Program Document, send an email to: compliance@life-mi.com

Annual Declaration of Compliance

California Compliance Law Statement

Life Molecular Imaging “LMI” is committed to compliance laws and regulations that pertains to its business, sales, research, , and marketing practices in the countries in which LMI operates.  LMI is in compliance with its Compliance Program (CCP) and Cal. Health & Safety Code §§ 119400-119402. Our Compliance Program contains the elements of an effective compliance program identified in the “Compliance Program Guidance for Pharmaceutical Manufacturers” published by the Office of the Inspector General, U.S. Department of Health and Human Services (“HHS-OIG Guidance”). In addition, LMI has adopted the “Code on Interactions with Healthcare Professionals” published by The Pharmaceutical Research and Manufacturers of America (the “PhRMA Code”) and has policies, procedures and processes designed to help ensure compliance with the PhRMA Code.

In accordance with Chapter 8, Part 15, Division 104 of the California Health and Safety Code (§§ 119400-119402), LMI has established an annual aggregate dollar limit of $2,000 per healthcare professional licensed in California for the following items: 1) meals provided in connection with informational presentations or scientific exchange; 2) educational items intended to enhance patient care (excluding items of minimal monetary value and/or of no independent value (e.g. printedadvertising, reimbursement fact sheets)) and items for the benefit of and distribution to patients/care givers.

Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS

  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.

ADVERSE REACTIONS:

  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).

DRUG INTERACTIONS

  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

OVERDOSAGE
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.

SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

.
.
.
.
.